Oral hypoglycemic agent, derivative of sulfonylureas of the second generation. It stimulates the secretion of insulin with β-cells of the pancreas, increases the release of insulin. Acts mainly during the second stage of insulin secretion. Increases the sensitivity of peripheral tissues to insulin and the degree of its binding to target cells. Has hypolipidemic action, reduces thrombogenic properties of blood.
Type 1 diabetes mellitus, ketoacidosis, diabetic precoma and coma, severe microcirculation disorders, infectious diseases, marked renal and / or liver dysfunction. Hypersensitivity to derivatives of sulfonylurea and sulfonamide preparations. Do not use for serious surgical procedures.
Hypoglycaemia, gastrointestinal disorders (heartburn, lack of appetite, taste of metal in the mouth, nausea, vomiting, diarrhea, hypothyroidism, allergic reactions (skin rash, eczema, urticaria), cholestasis, impaired liver function, impaired sensitivity, hemopoiesis, rarely possible Photosensitization.
The dose is set individually, depending on the age, severity of diabetes, fasting glycemia and 2 hours after meals.
The average dose is 2.5-15 mg / day, the frequency of reception is 1-3 times / day. Take for 20-30 minutes before meals. In doses of more than 15 mg / day is used in rare cases and does not cause a significant increase in hypoglycemic effect.
For elderly patients, the initial dose is 1 mg / day.
When switching from biguanides, the initial dose of glibenclamide is 2.5 mg / day. Biguanides should be discarded, and the dose of glibenclamide, if necessary, may be increased by 2.5 mg every 5-6 days until the carbohydrate metabolism is compensated. In the absence of compensation within 4-6 weeks, it is necessary to plan combined therapy with glibenclamide and biguanides.